Eozinofili ve Sistemik Semptomların Eşlik Ettiği İlaç Döküntüsü (Dress ) ile Eş Zamanlı Sitomegalovirus Enfeksiyonu: Bir Olgu Sunumu

Öz

Eozinofili ve sistemik semptomların eşlik ettiği ilaç döküntüsü (DRESS) genellikle antikonvülzanların dahil olduğu birtakım ilaçlara, 3-6 hafta maruz kaldıktan sonra görünen şiddetli çoklu organ aşırı duyarlılık reaksiyonu ile karakterizedir. Birçok çalışmada insan Herpes Virüs 6 (HHV-6) reaktivasyonunun DRESS gelişimine katkıda bulunduğu gösterilmiştir. Bununla birlikte yakın dönemdeki çalışmalarda diğer Herpes virüslerden, Herpes virüs 7 (HHV-7), Ebstein-Barr virüs (EBV) ve Sitomegalovirus (CMV) reaktivasyonunun DRESS gelişimiyle ilişkili olduğu gösterilmiştir. Burada febril konvülsiyon profilaksisi için fenitoin kullanmakta olan 2 yaşında bir kız çocuğunda DRESS gelişimi ve eş zamanlı CMV viral yük varlığı gösterilmiştir.

Anahtar Kelimeler

• Sitomegalovirus enfeksiyonu, Eozinofili ve sistemik semptomların eşlik ettiği ilaç döküntüsü, DRESS sendromu, İntravenöz immunoglobulin

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Concurrent with Cytomegalovirus Infection: A Case Report

Öz

Drug rash with eosinophilia and systemic symptoms (DRESS) is characterized by a severe multiorgan hypersensitivity reaction that usually appears after a 3–6-week exposure to certain drugs, including anticonvulsants. Many reports have revealed that human herpesvirus 6 (HHV-6) reactivation contributes to the development of DRESS. In addition, recent articles have shown that reactivation of other herpesviruses such as human herpesvirus 7 (HHV-7), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) might be also implicated in development of DRESS. Here we report development of the DRESS syndrome and concurrent presence of CMV viral load in a 2-year-old girl who was on phenytoin prophylaxis for febrile seizure

Anahtar Kelimeler

• Cytomegalovirus infection, Drug rash with eosinophilia and systemic symptoms, DRESS syndrome, Intravenous immunoglobulin

Kaynakça

1. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.
2. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013; 68:693.e1.
3. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol 2013; 68:709.e1.
4. Criado PR, Criado RFJ, Avancini JM, Santi CG. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Drug-Induced Hypersensitivity Syndrome (DIHS): A review of current concepts. An Bras Dermatol 2012;87:435-49.
5. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halew S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist? Br J Dermatol 2007;156:609-711.
6. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS syndrome: A literature review. Am J Med 2011;124:588–97.
7. Descamps V, Valance A, Edlinger C, Fillet AM, Grossin M, Lebrun- Vignes B, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
8. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006;155:301-6.

9. Hashizume H, Takigawa M. Drug-induced hypersensitivity syn- drome associated with cytomegalovirus reactivation: Immuno- logical characterization of pathogenic T cells. Acta Derm Venereol (Stockh) 2005;85:47–50.
10. Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F, Ranger Rogez S, et al. Drug-induced hypersensitivity syndrome associated with Epstein–Barr virus infection. Br J Dermatol 2003; 148:1032–34.
11. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007;157:934-40.
12. Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): A multiorgan antiviral T cell response. Sci Transl Med 2010;2:46ra62.
13. Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: Their relation to the clinical phenotype and therapeutic outcome. Allergy 2014; 69: 798–805.
14. Aihara M, Sugita Y, Takehashi, Nagatani T, Arata S, Takeuchi K, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001;144:1231–4.
15. Viard L, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with intravenous immunoglobulin. Science 1998;282:490–3.
16. Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Nevirapine- associated dress syndrome with intravenous immunoglobulin (IVIG). J Drugs Dermatol 2005;4:510–3.
17. Schneck J, Fagot JP, Sekula P, Sassalos B, Roujeau JC, Mockhenhaupt M. Effects of treatments of the mortality of Steven Johnson syndrome and toxic epidermal necrolysis; a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008;58:33–40.
18. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS SYNDROME): An update. Dermatology 2003;206:353–6.
19. Kano Y, Inaoka M, Sakuma K, Shihora T. Virus reactivation and intravenous immunoglobulin (IVIG) therapy of drug-induced hypersensitivity syndrome. Toxicology 2005;209:165-7.